{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T12:51:10Z","timestamp":1765889470677,"version":"3.40.2"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,22]],"date-time":"2025-03-22T00:00:00Z","timestamp":1742601600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,3,22]],"date-time":"2025-03-22T00:00:00Z","timestamp":1742601600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Dermatol Res"],"DOI":"10.1007\/s00403-025-04033-0","type":"journal-article","created":{"date-parts":[[2025,3,23]],"date-time":"2025-03-23T06:46:10Z","timestamp":1742712370000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["A real-world study of ixekizumab use patterns, switching and efficacy in patients with plaque psoriasis"],"prefix":"10.1007","volume":"317","author":[{"given":"Zheng","family":"Zhao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhanglei","family":"Mu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianzhong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lin","family":"Cai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,3,22]]},"reference":[{"issue":"Pt 2","key":"4033_CR1","doi-asserted-by":"publisher","first-page":"113474","DOI":"10.1016\/j.intimp.2024.113474","volume":"143","author":"Z Zhao","year":"2024","unstructured":"Zhao Z, Mu Z, Zhao Y, Zhang J, Cai L (2024) Efficacy, drug survival, safety and metabolic parameters of Ixekizumab in patients with moderate-to-severe psoriasis in China: A two-year real-world study. Int Immunopharmacol 143(Pt 2):113474","journal-title":"Int Immunopharmacol"},{"issue":"3","key":"4033_CR2","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1111\/jdv.19682","volume":"38","author":"L Mastorino","year":"2024","unstructured":"Mastorino L, Dapavo P, Burzi L, Rosset F, Giunipero di Corteranzo I, Leo F, Verrone A, Stroppiana E, Ortoncelli M, Ribero S, Quaglino P (2024) Drug survival, effectiveness and safety of Ixekizumab for moderate-to-severe psoriasis up to 5 years. J Eur Acad Dermatol Venereol 38(3):568\u2013575","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"6","key":"4033_CR3","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1016\/j.jaad.2021.04.093","volume":"86","author":"LR Ye","year":"2022","unstructured":"Ye LR, Yan BX, Chen XY, Chen SQ, Chen JQ, Man XY, Chinese Psoriasis Real World Evidence Research Group (CPRWERG) (2022) Extended dosing intervals of Ixekizumab for psoriasis: A single-center, uncontrolled, prospective study. J Am Acad Dermatol 86(6):1348\u20131350","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"4033_CR4","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1684\/ejd.2022.4330","volume":"32","author":"Y Li","year":"2022","unstructured":"Li Y, Yu Y, Wang Y, Lu J, Yi X, Yu N, Ding Y, Shi Y (2022) Ixekizumab four-week dosing is comparable to two-week dosing in psoriasis patients and reduces treatment costs: experience in a real-world setting over a 12-week period. Eur J Dermatol 32(5):618\u2013622","journal-title":"Eur J Dermatol"},{"issue":"3","key":"4033_CR5","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1080\/09546634.2018.1506081","volume":"30","author":"T Bokor-Billmann","year":"2019","unstructured":"Bokor-Billmann T, Schakel K (2019) No need to change the drug class: ixekizumab- following secukinumab-therapy in psoriasis. J Dermatolog Treat 30(3):216\u2013220","journal-title":"J Dermatolog Treat"},{"issue":"6","key":"4033_CR6","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1684\/ejd.2020.3945","volume":"30","author":"T Torres","year":"2020","unstructured":"Torres T, Tavares Bello R, Paiva Lopes MJ, Menezes Brandao F, Ferreira A, Ferreira P, Varela P, Sousa Basto A, Pereira M, Selores M, Marques Pinto G, Pinto Soares A, Filipe P (2020) Portuguese recommendations for the treatment of psoriasis with biologic therapy. Eur J Dermatol 30(6):645\u2013654","journal-title":"Eur J Dermatol"},{"issue":"3","key":"4033_CR7","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1111\/bjd.15656","volume":"177","author":"A Blauvelt","year":"2017","unstructured":"Blauvelt A, Reich K, Warren RB, Szepietowski JC, Sigurgeirsson B, Tyring SK, Messina I, Bhosekar V, Oliver J, Papavassilis C, Frueh J, Langley RGB (2017) Secukinumab re-initiation achieves regain of high response levels in patients who interrupt treatment for moderate to severe plaque psoriasis. Br J Dermatol 177(3):879\u2013881","journal-title":"Br J Dermatol"},{"issue":"6","key":"4033_CR8","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1111\/jdv.14163","volume":"31","author":"A Blauvelt","year":"2017","unstructured":"Blauvelt A, Papp KA, Sofen H, Augustin M, Yosipovitch G, Katoh N, Mrowietz U, Ohtsuki M, Poulin Y, Shrom D, Burge R, See K, Mallbris L, Gordon KB (2017) Continuous dosing versus interrupted therapy with Ixekizumab: an integrated analysis of two phase 3 trials in psoriasis. J Eur Acad Dermatol Venereol 31(6):1004\u20131013","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"4033_CR9","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1111\/jdv.15292","volume":"33","author":"Y Umezawa","year":"2019","unstructured":"Umezawa Y, Torisu-Itakura H, Morisaki Y, ElMaraghy H, Nakajo K, Akashi N, Saeki H, Japanese Ixekizumab Study Group (2019) Long-term efficacy and safety results from an open-label phase III study (UNCOVER-J) in Japanese plaque psoriasis patients: impact of treatment withdrawal and retreatment of Ixekizumab. J Eur Acad Dermatol Venereol 33(3):568\u2013576","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"4","key":"4033_CR10","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1080\/09546634.2016.1249820","volume":"28","author":"K Reich","year":"2017","unstructured":"Reich K, Leonardi C, Lebwohl M, Kerdel F, Okubo Y, Romiti R, Goldblum O, Dennehy EB, Kerr L, Sofen H (2017) Sustained response with Ixekizumab treatment of moderate-to-severe psoriasis with scalp involvement: results from three phase 3 trials (UNCOVER-1, UNCOVER-2, UNCOVER-3). J Dermatolog Treat 28(4):282\u2013287","journal-title":"J Dermatolog Treat"},{"issue":"12","key":"4033_CR11","doi-asserted-by":"publisher","first-page":"2797","DOI":"10.1007\/s13555-022-00834-7","volume":"12","author":"B Lockshin","year":"2022","unstructured":"Lockshin B, Harrison RW, McLean RR, Crabtree MM, Konicek BW, Zhu B, Malatestinic WN, Atiya B, Murage MJ, Burge RT (2022) Outcomes in Ixekizumab patients following exposure to Secukinumab and other biologics in the corevitas psoriasis registry. Dermatol Ther (Heidelb) 12(12):2797\u20132815","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"6","key":"4033_CR12","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1111\/bjd.17580","volume":"180","author":"A Conti","year":"2019","unstructured":"Conti A, Peccerillo F, Amerio P, Balato A, Bardazzi F, Bianchi L, Burlando M, Cannav\u00f2 SP, Chiricozzi A, Dapavo P, De Simone C, Fargnoli MC, Gambardella A, Gisondi P, Malagoli P, Malara G, Mugheddu C, Offidani AM, Piaserico S, Prignano F, Stingeni L, Pellacani G (2019) Efficacy and safety of switching to Ixekizumab in Secukinumab nonresponder patients with psoriasis: results from a multicentre experience. Br J Dermatol 180(6):1547\u20131548","journal-title":"Br J Dermatol"},{"issue":"3","key":"4033_CR13","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/j.jaad.2021.06.878","volume":"86","author":"A Blauvelt","year":"2022","unstructured":"Blauvelt A, Shi N, Somani N, Burge R, Zhu B, Ridenour TL, Lew CR, Zimmerman NM, Atiya B, Murage MJ (2022) Comparison of two-year treatment adherence, persistence, discontinuation, reinitiation, and switching between psoriasis patients treated with Ixekizumab or Secukinumab in real-world settings. J Am Acad Dermatol 86(3):581\u2013589","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"4033_CR14","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1111\/bjd.16497","volume":"178","author":"C Paul","year":"2018","unstructured":"Paul C (2018) Ixekizumab or Secukinumab in psoriasis: what difference does it make? Br J Dermatol 178(5):1003\u20131005","journal-title":"Br J Dermatol"},{"key":"4033_CR15","doi-asserted-by":"publisher","first-page":"1341708","DOI":"10.3389\/fimmu.2023.1341708","volume":"14","author":"L Gargiulo","year":"2024","unstructured":"Gargiulo L, Ibba L, Malagoli P, Balato A, Bardazzi F, Burlando M, Carrera CG, Damiani G, Dapavo P, Dini V, Gaiani FM, Girolomoni G, Guarneri C, Lasagni C, Loconsole F, Marzano AV, Megna M, Mercuri SR, Travaglini M, Costanzo A, Narcisi A (2024) Drug survival of IL-12\/23, IL-17 and IL-23 inhibitors for moderate-to-severe plaque psoriasis: a retrospective multicenter real-world experience on 5932 treatment courses - IL PSO (Italian landscape psoriasis). Front Immunol 14:1341708","journal-title":"Front Immunol"},{"issue":"1","key":"4033_CR16","doi-asserted-by":"publisher","first-page":"e14584","DOI":"10.1111\/dth.14584","volume":"34","author":"C Bonifati","year":"2021","unstructured":"Bonifati C, Morrone A, Cristaudo A, Graceffa D (2021) Effectiveness of anti-interleukin 23 biologic drugs in psoriasis patients who failed anti-interleukin 17 regimens. A real-life experience. Dermatol Ther 34(1):e14584","journal-title":"Dermatol Ther"},{"issue":"9625","key":"4033_CR17","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1016\/S0140-6736(08)60726-6","volume":"371","author":"KA Papp","year":"2008","unstructured":"Papp KA, Langley RG, Lebwohl M, Krueger GG, Szapary P, Yeilding N, Guzzo C, Hsu MC, Wang Y, Li S, Dooley LT, Reich K, PHOENIX 2 study investigators (2008) Efficacy and safety of Ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet 371(9625):1675\u20131684","journal-title":"Lancet"},{"issue":"9","key":"4033_CR18","doi-asserted-by":"publisher","first-page":"2691","DOI":"10.3390\/jcm13092691","volume":"13","author":"M Megna","year":"2024","unstructured":"Megna M, Ruggiero A, Martora F, Vallone Y, Guerrasio G, Potestio L (2024) Long-Term efficacy and safety of Guselkumab in psoriasis patients who failed Anti-IL17: A Two-Year Real-Life study. J Clin Med 13(9):2691","journal-title":"J Clin Med"},{"issue":"3","key":"4033_CR19","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1080\/09546634.2021.1892024","volume":"33","author":"K Reich","year":"2022","unstructured":"Reich K, Conrad C, Kristensen LE, Smith SD, Puig L, Rich P, Sapin C, Holzkaemper T, Koppelhus U, Schuster C (2022) Network meta-analysis comparing the efficacy of biologic treatments for achieving complete resolution of nail psoriasis. J Dermatolog Treat 33(3):1652\u20131660","journal-title":"J Dermatolog Treat"}],"container-title":["Archives of Dermatological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-025-04033-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00403-025-04033-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-025-04033-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,23]],"date-time":"2025-03-23T06:46:12Z","timestamp":1742712372000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00403-025-04033-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,22]]},"references-count":19,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4033"],"URL":"https:\/\/doi.org\/10.1007\/s00403-025-04033-0","relation":{},"ISSN":["1432-069X"],"issn-type":[{"value":"1432-069X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,22]]},"assertion":[{"value":"11 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 February 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 March 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol was approved by the Ethics Committee of Peking University People\u2019s Hospital (2022PHB397-001).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"614"}}